Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial

Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial

Objective: Management of heavily pre-treated platinum-resistant ovarian cancer remains a therapeutic challenge. Outcomes are poor with non-platinum, single-agent chemotherapy (CT); however, molecularly targeted anticancer therapies provide new options. Methods: This open-label, investigator-initiate...

Full description

Bibliographic Details
Main Authors: Choi, C.H (Author), Joung, J.-G (Author), Kim, B.-G (Author), Kim, H.S (Author), Kim, J.-W (Author), Kim, S. (Author), Korean Gynecologic Oncology Group (KGOG) investigators (Author), Lee, J.B (Author), Lee, J.-Y (Author), Park, E. (Author)
Format: Article
Language:English
Published: Korean Society of Gynecologic Oncology and Colposcopy 2022
Subjects:
Biomarker
Immunotherapy
Molecular Targeted Therapy
Ovarian Cancer
Platinum Resistant
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items